Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 83422E204 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Perceptive Advisors LLC
13D/A
Amendment 10
|
11.2% |
8/14/2026
Event 6/30/2026
|
|
| Perceptive Advisors LLC | 11.2% | ||
| Joseph Edelman | 11.2% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 11.2% | ||
| Perceptive Xontogeny Venture Fund, LP | 0.1% | ||
|
Vestal Point Capital, LP
13G/A
Amendment 2
|
4.8% |
8/14/2026
Event 6/30/2026
|
|
| Vestal Point Capital, LP | 4.8% | ||
| Ryan Wilder | 4.8% | ||
|
FMR LLC
13G
|
7.0% |
8/6/2026
Event 6/30/2026
|
|
| FMR LLC | 7.0% | ||
| Abigail P. Johnson | 7.0% | ||
| BlackRock, Inc. 13G | 6.5% |
7/30/2026
Event 6/30/2026
|
|
|
RA Capital Management, L.P.
13D/A
Amendment 13
|
11.9% |
6/24/2026
Event 6/22/2026
|
|
| RA Capital Management, L.P. | 11.9% | ||
| Peter Kolchinsky | 11.9% | ||
| Rajeev Shah | 11.9% | ||
| RA Capital Healthcare Fund, L.P. | 11.8% | ||
|
Invus Global Management, LLC
13G/A
Amendment 5
|
10.0% |
5/5/2026
Event 3/31/2026
|
|
| Invus Public Equities, L.P. | 8.7% | ||
| Invus Public Equities Advisors, LLC | 8.7% | ||
| Invus Global Management, LLC | 8.7% | ||
| Siren, L.L.C. | 8.7% | ||
| Avicenna Life Sci Master Fund LP | 1.4% | ||
| Avicenna Life Sci Master GP LLC | 1.4% | ||
| Ulys, L.L.C. | 1.4% | ||
| Raymond Debbane | 10.0% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.7% |
4/27/2026
Event 3/31/2026
|
|
|
RA Capital Management, L.P.
13D/A
Amendment 12
|
9.9% |
3/17/2026
Event 3/13/2026
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.8% | ||
|
Perceptive Advisors LLC
13D/A
Amendment 9
|
12.9% |
3/11/2026
Event 3/9/2026
|
|
| Perceptive Advisors LLC | 12.9% | ||
| Joseph Edelman | 12.9% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 12.8% | ||
| Perceptive Xontogeny Venture Fund, LP | 0.1% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 11
|
9.9% |
3/10/2026
Event 3/6/2026
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.8% | ||
|
Vestal Point Capital, LP
13G
|
7.5% |
2/17/2026
Event 12/31/2025
|
|
| Vestal Point Capital, LP | 7.5% | ||
| Ryan Wilder | 7.5% | ||
|
Adage Capital Management, L.P.
13G/A
Amendment 2
|
1.8% |
2/12/2026
Event 12/31/2025
|
|
| Adage Capital Management, L.P. | 1.8% | ||
| Robert Atchinson | 1.8% | ||
| Phillip Gross | 1.8% | ||
|
Adage Capital Management, L.P.
13G/A
Amendment 1
|
5.1% |
11/13/2025
Event 9/30/2025
|
|
| Adage Capital Management, L.P. | 5.1% | ||
| Robert Atchinson | 5.1% | ||
| Phillip Gross | 5.1% | ||
|
Commodore Capital LP
13G/A
Amendment 1
|
0% |
8/14/2025
Event 6/30/2025
|
|
| Commodore Capital LP | 0% | ||
| Commodore Capital Master LP | 0% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 10
|
9.9% |
8/14/2025
Event 8/12/2025
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.8% | ||
| BlackRock, Inc. 13G | 6.1% |
7/17/2025
Event 6/30/2025
|
|
|
Vestal Point Capital, LP
13G/A
Amendment 1
|
2.3% |
5/15/2025
Event 3/31/2025
|
|
| Vestal Point Capital, LP | 2.3% | ||
| Ryan Wilder | 2.3% | ||
|
Adage Capital Management, L.P.
13G
|
8.7% |
5/12/2025
Event 3/31/2025
|
|
| Adage Capital Management, L.P. | 8.7% | ||
| Robert Atchinson | 8.7% | ||
| Phillip Gross | 8.7% | ||
|
Invus Global Management, LLC
13G/A
Amendment 4
|
9.6% |
4/17/2025
Event 3/31/2025
|
|
| Invus Public Equities, L.P. | 8.3% | ||
| Invus Public Equities Advisors, LLC | 8.3% | ||
| Invus Global Management, LLC | 8.3% | ||
| Siren, L.L.C. | 8.3% | ||
| Avicenna Life Sci Master Fund LP | 1.3% | ||
| Avicenna Life Sci Master GP LLC | 1.3% | ||
| Ulys, L.L.C. | 1.3% | ||
| Raymond Debbane | 9.6% | ||
|
Commodore Capital LP
13G
|
7.6% |
2/25/2025
Event 2/18/2025
|
|
| Commodore Capital LP | 7.6% | ||
| Commodore Capital Master LP | 7.6% | ||
|
Perceptive Advisors LLC
13D/A
Amendment 8
|
15.6% |
2/21/2025
Event 2/19/2025
|
|
| Perceptive Advisors LLC | 15.6% | ||
| Joseph Edelman | 15.6% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 15.5% | ||
| Perceptive Xontogeny Venture Fund, LP | 0.1% | ||
|
Invus Global Management, LLC
13G/A
Amendment 3
|
9.4% |
2/12/2025
Event 12/31/2024
|
|
| Invus Public Equities, L.P. | 8.2% | ||
| Invus Public Equities Advisors, LLC | 8.2% | ||
| Invus Global Management, LLC | 8.2% | ||
| Siren, L.L.C. | 8.2% | ||
| Avicenna Life Sci Master Fund LP | 1.2% | ||
| Avicenna Life Sci Master GP LLC | 1.2% | ||
| Ulys, L.L.C. | 1.2% | ||
| Raymond Debbane | 9.4% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 8.35 k | $60.4 k |
| 2026 Q2 | 162 | 115 M | $1.15 B |
| 2026 Q1 | 152 | 99.9 M | $719 M |
| 2025 Q4 | 131 | 81.4 M | $459 M |
| 2025 Q3 | 130 | 81.4 M | $502 M |
| 2025 Q2 | 116 | 82.6 M | $402 M |
| 2025 Q1 | 127 | 78.8 M | $292 M |
| 2024 Q4 | 98 | 36.3 M | $145 M |
| 2024 Q3 | 101 | 35.9 M | $250 M |
| 2024 Q2 | 85 | 37.7 M | $214 M |
| 2024 Q1 | 61 | 35.1 M | $467 M |
| 2023 Q4 | 42 | 16.6 M | $102 M |
| 2023 Q3 | 37 | 16.2 M | $40.7 M |
| 2023 Q2 | 35 | 16.3 M | $85.6 M |
| 2023 Q1 | 40 | 15.8 M | $74.8 M |
| 2022 Q4 | 37 | 15.3 M | $85.7 M |
| 2020 Q3 | 1 | 307 k | $623 k |